Pharmaxis Share Price and Company Fundamentals
Last traded: Today at 5:10 AM
Pharmaxis Ltd engages in the research, development, and commercialization of healthcare products for the treatment of fibrotic and inflammatory diseases worldwide. The company operates through two segments, Mannitol Respiratory Business and New Drug Development. It offers Bronchitol, an inhaled dry powder for the treatment of cystic fibrosis; and Aridol, an airways inflammation test that is used to identify twitchy or hyper-responsive airways, as well as to assist in diagnosing and managing asthma. The company's product pipeline consists of amine oxidase inhibitors comprising semicarbazide-sensitive amine oxidase for diabetic retinopathy; selective lysyl oxidase like inhibitors targeting chronic fibrotic diseases, such as NASH, pulmonary fibrosis, kidney fibrosis, and cardiac fibrosis; and pan-lysyl oxidase inhibitors targeting myelofibrosis and other cancers, and scarring. It is also developing Orbital, a dry powder inhaler to deliver high drug doses to lungs. Pharmaxis Ltd was incorporated in 1998 and is headquartered in Frenchs Forest, Australia.
|Primary activities||Pharmaxis is a pharmaceutical research company with approved products in various markets around the world, and a drug discovery program dedicated to finding new treatments for patients in areas of high unmet clinical need in inflammatory and fibrotic dise|
|Industry / Sector||Drug Manufacturers—Specialty & Generic / Healthcare|
|Full time employees||63|
|Mailing address||20 Rodborough Road Frenchs Forest NSW 2086 Australia|
|Phone / Fax||61 2 9454 7200 / 61 2 9451 3622|
|Share registry||COMPUTERSHARE INVESTOR SERVICES PTY LIMITED|
Pharmaxis does not pay dividends.
As of Jan 2022, following are the company executives and directors listed on Pharmaxis.
|Mr. Gary Jonathan Phillips BPharm, MBA||CEO, MD & Director||60||631.58k|
|Dr. Brett Charlton MBBS Ph.D., Ph.D.||Co-Founder & Medical Director||65||501.31k|
|Mr. David Morris McGarvey BA, CA, CPA||CFO & Company Sec.||65||505.4k|
|Dr. Wolfgang G. Jarolimek B.Sc. Ph.D., Ph.D.||Head of Drug Discovery||57||493.1k|
|Ms. Kristen Morgan B.Sc., BSc, PGDipBusAdmin, MMedSc||Alliance Management - Head of Medical & Regulatory Affairs||49||316.94k|
|Mr. Cameron David Billingsley||Gen. Counsel||44|
|Dr. Dieter Hamprecht||Head of Chemistry for Drug Discovery|
Profitability and management effectiveness
Return on equity
Profitability ratios are a class of financial metrics that are used to assess a business's ability to generate earnings relative to its revenue, operating costs, balance sheet assets, and shareholders' equity over time, using data from a specific point in time.
The return on equity signifies how well the management is running the company in terms of capital management. The ideal return on equity is greater than 10%. The return on equity is calculated as net income divided by total share holders equity.
Valuation and Trading Info
The market capitalization of Pharmaxis is and its enterprise value is .
The PXS's stocks Beta value is 0.58 making it 42% less volatile compared to ASX market index. Technology stocks and small caps tend to have higher betas than the market benchmark. This indicates that adding the stock to a portfolio will increase the portfolio’s risk, but also increase its expected return. On the other hand utility stocks often have low betas because they tend to move more slowly than market averages.
Companies similar to Pharmaxis (PXS)
Pharmaxis (ASX:PXS) Frequently Asked Questions
1. What is Pharmaxis's Stock Symbol?
Pharmaxis trades on ASX under the ticker symbol "PXS".
2. What is Pharmaxis's stock price today?
One share of PXS stock can currently be purchased for approximately $0.105.
3. How can I contact Pharmaxis?
Pharmaxis's mailing address is 20 Rodborough Road Frenchs Forest NSW 2086 Australia. The company can be reached via phone at 61 2 9454 7200.
4. What is Pharmaxis's official website?
The official website of Pharmaxis is https://www.pharmaxis.com.au.
5. Which share registry manages Pharmaxis's stock?
Pharmaxis's stock is managed by COMPUTERSHARE INVESTOR SERVICES PTY LIMITED.